Since risk comes from decisions on limited information, Pheast builds in flexibility to adjust processes as information becomes available.

In an exciting development for drug development and patient care, the FDA has officially accepted the first submission of an organ-on-a-chip technology under its Innovative Science and Technology ...

By thoroughly analyzing CMC processes, Mitul Tilala ensures each step is carefully evaluated to identify any areas of concern ...

The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...

New drug discovery is a critical step for improving patients' lives. First, researchers must identify molecules in the body's cells that help drive disease, as these are potential targets for new ...

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studiesAppili provides update on Aditxt transaction and encourages ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Laboratories face a series of upcoming deadlines to comply with stricter FDA oversight of in-house tests. Here are five ...

Oct 28 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will pay Monte Rosa ... manufacture and sell some drug candidates, the U.S.-based biotech firm said on Monday.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Monday said it is scheduled for an FDA Type C meeting to discuss the design of ...

TOKYO :Japanese medical equipment maker Olympus Corp said on Monday that Chief Executive Stefan Kaufmann has stepped down after allegations he purchased illegal drugs, sending its shares sharply ...

TOKYO (Reuters) -Japanese endoscope manufacturer Olympus Corp said on Monday it has sacked Chief Executive Stefan Kaufmann after an allegation that he had purchased illegal drugs, sending its ...